Bluerock Creek

Bluerock Announces Launch of Institutional Division, Taps Industry Veteran Doug Kinney to Spearhead Initiative

Retrieved on: 
Tuesday, November 14, 2023
Invictus, Sale, Duff, Greenhill & Co., NAV, REIT, Duff & Phelps, BRG, Total shareholder return, TSR, The Carlyle Group, Growth, BHM, BentallGreenOak, IRR, Cryptocurrency, Financial services, Real estate, Fund, Bluerock Creek

NEW YORK, Nov. 14, 2023 /PRNewswire/ -- Bluerock, a leading alternative asset fund manager, announced today that it is expanding into institutional distribution and that it has appointed Doug Kinney to the role of Managing Director, Head of Institutional Capital to spearhead the initiative.

Key Points: 
  • NEW YORK, Nov. 14, 2023 /PRNewswire/ -- Bluerock, a leading alternative asset fund manager, announced today that it is expanding into institutional distribution and that it has appointed Doug Kinney to the role of Managing Director, Head of Institutional Capital to spearhead the initiative.
  • Mr. Kinney will be responsible for directing the company's institutional channel, building on the firm's formidable investment capabilities and track record.
  • "The addition of Doug Kinney to the team positions us well to execute on this critical next phase of growth, said Ramin Kamfar, CEO and founder of Bluerock.
  • "Doug brings the energy, insight, and institutional industry experience to build this new business vertical, capitalizing on Bluerock's established record of investment success across multiple strategies and multiple cycles," Mr. Kamfar adds.

Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale

Retrieved on: 
Tuesday, October 10, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Multimedia, Investment, IPSC, Research, Trial of the century, Cell, USD, Bayer, Medication, Therapy, Shoulder, Patient, Pharmaceutical industry, Fine chemical, Bluerock Creek

Bayer AG announced today the opening of its first Cell Therapy Launch Facility in Berkeley, California to create the capacity to bring cell therapies to patients on a global scale.

Key Points: 
  • Bayer AG announced today the opening of its first Cell Therapy Launch Facility in Berkeley, California to create the capacity to bring cell therapies to patients on a global scale.
  • In addition, it includes space for a second module of production suites to support additional cell therapies as Bayer’s portfolio advances.
  • BlueRock Therapeutics LP is a clinical stage, cell therapy company and wholly owned, independently operated subsidiary of Bayer AG.
  • “Having access to this Cell Therapy Launch Facility is central to our goal to deliver impactful cell therapies from our pipeline to patients in need,” said Seth Ettenberg, President & CEO of BlueRock Therapeutics.

BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery and manufacture of regulatory T cell (Treg) based therapies

Retrieved on: 
Thursday, August 3, 2023
Therapy, Risk, Inflammation, Cell, TF, MD, Bluerock Creek, Patient, Machine learning, Immune system, FDA, Autoimmunity, Pharmaceutical industry, Regulatory T cell, Bayer

Agreement includes option for BlueRock to license TF combinations emerging from the collaboration as well as an option to license bit.bio's opti-ox™ precision cell programming technology for the manufacture and subsequent development of iPSC-derived Treg cell therapies.

Key Points: 
  • Agreement includes option for BlueRock to license TF combinations emerging from the collaboration as well as an option to license bit.bio's opti-ox™ precision cell programming technology for the manufacture and subsequent development of iPSC-derived Treg cell therapies.
  • bit.bio receives an upfront payment from BlueRock and is eligible to receive milestone payments and royalties on worldwide sales of all therapies resulting from the collaboration.
  • "We are delighted to partner with the team at BlueRock, who are world-leaders in iPSC-derived cell therapies, and together address the significant unmet needs of these patients."
  • The agreement also includes options for BlueRock to license bit.bio's opti-ox precision cell programming technology to control the expression of TF combinations within Treg cell therapies.

BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery and manufacture of regulatory T cell (Treg) based therapies

Retrieved on: 
Thursday, August 3, 2023
Therapy, Risk, Inflammation, Cell, TF, MD, Bluerock Creek, Patient, Machine learning, Immune system, FDA, Autoimmunity, Pharmaceutical industry, Regulatory T cell, Bayer

Agreement includes option for BlueRock to license TF combinations emerging from the collaboration as well as an option to license bit.bio's opti-ox™ precision cell programming technology for the manufacture and subsequent development of iPSC-derived Treg cell therapies.

Key Points: 
  • Agreement includes option for BlueRock to license TF combinations emerging from the collaboration as well as an option to license bit.bio's opti-ox™ precision cell programming technology for the manufacture and subsequent development of iPSC-derived Treg cell therapies.
  • bit.bio receives an upfront payment from BlueRock and is eligible to receive milestone payments and royalties on worldwide sales of all therapies resulting from the collaboration.
  • "We are delighted to partner with the team at BlueRock, who are world-leaders in iPSC-derived cell therapies, and together address the significant unmet needs of these patients."
  • The agreement also includes options for BlueRock to license bit.bio's opti-ox precision cell programming technology to control the expression of TF combinations within Treg cell therapies.

BlueRock Therapeutics to use Rune Labs' clinical trial platform to better characterize Parkinson's disease state in cell therapy trials

Retrieved on: 
Tuesday, March 14, 2023
Disease, Bluerock Creek, Data, HIV disease progression rates, Research, Cell, Clinical trial, Apple Watch, Data analysis, Parkinson's disease, Dyskinesia, Data collection, Patient, RWE, Bayer, DSM-IV codes, Therapy, SAN, Labs, Partnership, Medical device, Pharmaceutical industry

BlueRock will use StriveStudy, Rune Labs' clinical trial platform featuring data collection and patient monitoring tools, to capture a holistic and precise picture of Parkinson's disease activity and to better engage patients in the study.

Key Points: 
  • BlueRock will use StriveStudy, Rune Labs' clinical trial platform featuring data collection and patient monitoring tools, to capture a holistic and precise picture of Parkinson's disease activity and to better engage patients in the study.
  • The partnership is the first deployment of Rune Labs' StriveStudy clinical trial platform, which enables more efficient studies of disease-modifying therapeutics to treat movement disorders.
  • Rune Labs' StriveStudy platform will capture multimodal data from people with Parkinson's to gain a better understanding of individual disease experience and build a dataset to characterize baseline symptom activity.
  • Rune Labs' clinical trial platform, StriveStudy, is available to biopharmaceutical companies working in the movement disorders space.

BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial

Retrieved on: 
Tuesday, March 14, 2023
Emerald, Disease, Bluerock Creek, HIV disease progression rates, Research, Medicine, Apple, Apple Watch, Parkinson's disease, Artificial intelligence, Data collection, Collaboration, Patient, Bayer, Therapy, Trial of the century, Tremor, Dyskinesia, Drug development, Labs, Rigidity, Movement disorder, Radio, Medical imaging, Pharmaceutical industry

CAMBRIDGE, Mass., March 14, 2023 /PRNewswire/ -- BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned, independently operated subsidiary of Bayer AG, today announced a collaboration with Rune Labs and Emerald Innovations focused on using wearable and invisible contactless digital health technology to improve monitoring and data collection for Parkinson's disease clinical trials.

Key Points: 
  • Rune Labs' StriveStudy platform and Emerald Innovations' Emerald wireless monitoring sensor will passively capture data on Parkinson's disease impact on function of fifty study participants in BlueRock's global non-interventional clinical study.
  • CAMBRIDGE, Mass., March 14, 2023 /PRNewswire/ -- BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned, independently operated subsidiary of Bayer AG, today announced a collaboration with Rune Labs and Emerald Innovations focused on using wearable and invisible contactless digital health technology to improve monitoring and data collection for Parkinson's disease clinical trials.
  • Emerald Innovations' Emerald monitoring biosensor belongs to a new class of sensors called "invisibles" that extract health metrics from radio signals, without wearable devices.
  • Our collaboration with BlueRock enables a data-driven clinical trial in Parkinson's while patients go about their normal lives," said Dr. Dina Katabi, Co-Founder of Emerald Innovations.

Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor

Retrieved on: 
Wednesday, January 25, 2023
Master of Science, COVID-19, Arrowhead Pharmaceuticals, Deloitte Technology Fast 500, Trustee, Woman, Health care, Erasmus University Rotterdam, The Advisory Board Company, Magazin, Bluerock Creek, Pharmaceutical Research and Manufacturers of America, Popular Executive Committee of Valencia, Business development, Harvard Business Review, Johnson & Johnson, Doctor of Philosophy, Executive Committee, Biotechnology Innovation Organization, Science, Biogen, Infection, Retirement, American City Business Journals, Therapy, MBA, Molecular biology, Vrije Universiteit Brussel, Overseer, IEEE Medal for Innovations in Healthcare Technology, Patient, Silicon, Growth, University, Management, Pharmaceutical industry, Biotechnology, Coronavirus, Biochemistry, Exelixis, Engineering, Ghent University, Bayer

SAN FRANCISCO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., will retire from his position as Chief Executive Officer (CEO), effective April 3, 2023. The Company’s Board of Directors has appointed industry veteran Marianne De Backer, MSc, Ph.D., MBA, currently Executive Vice President, Head of Pharmaceuticals Strategy, Business Development and Licensing/Open Innovation, and Member of the Executive Committee for Bayer Pharmaceuticals, as his successor, effective April 3, 2023. She will also join Vir’s Board of Directors.

Key Points: 
  • “George led the Company through a period of significant transformation, accelerated its growth and established a broad pipeline and strategy that we believe will support our long-term success.
  • In 2022, Vir was named the fastest growing company on the 2022 Deloitte Technology Fast 500 .
  • Prior to joining Vir, Dr. Scangos served as CEO and as a member of the Board of Biogen Inc. for six years.
  • “Vir represents an amalgamation of the best of what science and commitment to patients have to offer.

Bluerock Capital Markets Logs a Record $4+ Billion in Annual Capital Raise in 2022, Up 92% Over 2021's Record Inflows

Retrieved on: 
Tuesday, January 17, 2023
Ken Schwaber, Weather, RIA, REIT, Fund, BRG, BHM, Blackstone, DST, Barron's, AUM, Total, NYSE, TI, Sharpe ratio, Real estate investment trust, BCM, Policy, Growth, Sortino ratio, Sale, Adviser, CLO, Duff & Phelps, EfTEN Real Estate Fund III, Duff, Investment, 1031, Financial adviser, Real estate, Life insurance, Bluerock Creek

Bluerock Total Income+ finished 2022 up approximately 10% on the year while public REITs were down 22% and most peer funds were flat to negative.

Key Points: 
  • Bluerock Total Income+ finished 2022 up approximately 10% on the year while public REITs were down 22% and most peer funds were flat to negative.
  • Based on initial share price of $25.00 per share, TIPRX has paid more than $15.00 per share in total distributions to its shareholders.
  • In addition to these quarterly distributions, TIPRX NAV has grown more than 40% from $25 to $35.14 per share (as of 12.31.22).
  • Bluerock Fund Advisor, TI+ Fund's Advisor, was named a finalist for Asset Manager of the Year (AUM under $25 billion) by Barron's and Money Management Institute.

BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results

Retrieved on: 
Wednesday, November 9, 2022
IND, Adult, Bluerock Creek, Therapy, Survival rate, Survival, Company, Program, Cell, Awareness, Security (finance), Quality of life, Review, Forward-looking statement, New York Heart Association Functional Classification, Hand, Breakthrough, Two-phase electric power, Heart failure, Stem cell, SEC, PMDA, U.S. Securities and Exchange Commission, Data monitoring committee, Research, Patient, CEO, COVID-19, Investigational New Drug, NK1R, Nasdaq, Bone marrow, Phase, Achievement, Burn, Clinical trial, Physician, Pharmaceuticals and Medical Devices Agency, CMS, FDA, Trial of the century, GLOBE, Heart Failure Society of America, Medical device, BCDA, Safety, DSMB, Heart, Pharmaceutical industry, Medical imaging, Animal

Our team has delivered solid progress on our programs and business development initiatives this past quarter, said Peter Altman, Ph.D., President, and CEO.

Key Points: 
  • Our team has delivered solid progress on our programs and business development initiatives this past quarter, said Peter Altman, Ph.D., President, and CEO.
  • Throughout the third quarter, efforts developing the submission to PMDA for a third formal consultation continued and are substantially complete.
  • In October 2022, an update to www.CardiAMP.com , a website to educate patients and physicians about the clinical trial sponsored by BioCardia, went live.
  • The IND for this program was filed with FDA CBER in early November 2022 and the Company anticipates FDA approval in December 2022.

Senti Bio Announces New Employment Inducement Grants

Retrieved on: 
Friday, October 28, 2022
Company, Synthetic biology, HCC, DNA, CRC, Nasdaq, Gene, Colorectal cancer, Intelligence, Acute myeloid leukemia, Program, Senty Church, Bluerock Creek, GLOBE, Therapy, Plan, SAN, Employment, AML, Hepatocellular carcinoma, SNTI, Spark Therapeutics, Online gambling, Vaccine

These awards were made under the Companys 2022 Inducement Equity Plan (the Plan).

Key Points: 
  • These awards were made under the Companys 2022 Inducement Equity Plan (the Plan).
  • The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan.
  • The Plan was adopted by the Companys board of directors on August 5, 2022.
  • Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches.